Joshua Jennings
Stock Analyst at TD Cowen
(3.49)
# 867
Out of 4,868 analysts
68
Total ratings
46.77%
Success rate
6.1%
Average return
Main Sectors:
Stocks Rated by Joshua Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVR Anteris Technologies Global | Initiates: Buy | $15 | $4.05 | +270.37% | 1 | Jan 7, 2025 | |
| PODD Insulet | Maintains: Buy | $264 → $324 | $301.79 | +7.36% | 1 | Jan 3, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $100 → $110 | $101.37 | +8.51% | 7 | Dec 12, 2024 | |
| CBLL CeriBell | Maintains: Buy | $31 → $36 | $17.83 | +101.91% | 2 | Dec 9, 2024 | |
| TMDX TransMedics Group | Maintains: Buy | $175 → $120 | $124.00 | -3.23% | 9 | Nov 18, 2024 | |
| HUMA Humacyte | Reiterates: Buy | $10 | $2.36 | +323.73% | 2 | Oct 18, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $50 | $2.42 | +1,966.12% | 1 | Oct 2, 2024 | |
| PRCT PROCEPT BioRobotics | Maintains: Buy | $75 → $99 | $59.66 | +65.94% | 3 | Sep 16, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Hold | $143 → $119 | $90.55 | +31.42% | 1 | Sep 6, 2024 | |
| VCEL Vericel | Maintains: Buy | $55 → $60 | $41.78 | +43.61% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $83 → $80 | $84.25 | -5.04% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $45 | $19.57 | +129.94% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $100 → $70 | $73.98 | -5.38% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $185 | $150.73 | +22.74% | 1 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 | $29.80 | +34.23% | 4 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $400 | $373.26 | +7.16% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $38.03 | +57.77% | 4 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $34 | $20.41 | +66.63% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $18 | $6.77 | +165.88% | 3 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $114 → $125 | $81.01 | +54.30% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $25 | $19.43 | +28.67% | 1 | Dec 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 | $132.41 | -1.82% | 9 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $5 | $2.26 | +121.24% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $117 | $85.73 | +36.47% | 3 | May 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $450 | $7.87 | +5,617.92% | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $10.89 | +10.19% | 1 | Sep 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $306 → $275 | $168.59 | +63.12% | 1 | Feb 7, 2020 |
Anteris Technologies Global
Jan 7, 2025
Initiates: Buy
Price Target: $15
Current: $4.05
Upside: +270.37%
Insulet
Jan 3, 2025
Maintains: Buy
Price Target: $264 → $324
Current: $301.79
Upside: +7.36%
Boston Scientific
Dec 12, 2024
Maintains: Buy
Price Target: $100 → $110
Current: $101.37
Upside: +8.51%
CeriBell
Dec 9, 2024
Maintains: Buy
Price Target: $31 → $36
Current: $17.83
Upside: +101.91%
TransMedics Group
Nov 18, 2024
Maintains: Buy
Price Target: $175 → $120
Current: $124.00
Upside: -3.23%
Humacyte
Oct 18, 2024
Reiterates: Buy
Price Target: $10
Current: $2.36
Upside: +323.73%
Allurion Technologies
Oct 2, 2024
Initiates: Buy
Price Target: $50
Current: $2.42
Upside: +1,966.12%
PROCEPT BioRobotics
Sep 16, 2024
Maintains: Buy
Price Target: $75 → $99
Current: $59.66
Upside: +65.94%
Zimmer Biomet Holdings
Sep 6, 2024
Maintains: Hold
Price Target: $143 → $119
Current: $90.55
Upside: +31.42%
Vericel
Aug 27, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $41.78
Upside: +43.61%
Aug 13, 2024
Maintains: Hold
Price Target: $83 → $80
Current: $84.25
Upside: -5.04%
Aug 8, 2024
Maintains: Buy
Price Target: $135 → $45
Current: $19.57
Upside: +129.94%
Jul 25, 2024
Downgrades: Hold
Price Target: $100 → $70
Current: $73.98
Upside: -5.38%
Jul 18, 2024
Maintains: Buy
Price Target: $195 → $185
Current: $150.73
Upside: +22.74%
May 10, 2024
Downgrades: Hold
Price Target: $40
Current: $29.80
Upside: +34.23%
Apr 11, 2024
Maintains: Buy
Price Target: $365 → $400
Current: $373.26
Upside: +7.16%
Mar 12, 2024
Maintains: Outperform
Price Target: $50 → $60
Current: $38.03
Upside: +57.77%
Aug 4, 2023
Maintains: Outperform
Price Target: $52 → $34
Current: $20.41
Upside: +66.63%
May 11, 2023
Maintains: Outperform
Price Target: $14 → $18
Current: $6.77
Upside: +165.88%
Feb 10, 2023
Maintains: Outperform
Price Target: $114 → $125
Current: $81.01
Upside: +54.30%
Dec 30, 2022
Maintains: Outperform
Price Target: $6 → $25
Current: $19.43
Upside: +28.67%
Dec 13, 2022
Maintains: Outperform
Price Target: $130
Current: $132.41
Upside: -1.82%
Nov 11, 2022
Maintains: Outperform
Price Target: $7 → $5
Current: $2.26
Upside: +121.24%
May 27, 2022
Maintains: Outperform
Price Target: $125 → $117
Current: $85.73
Upside: +36.47%
Dec 7, 2021
Initiates: Outperform
Price Target: $450
Current: $7.87
Upside: +5,617.92%
Sep 3, 2020
Initiates: Outperform
Price Target: $12
Current: $10.89
Upside: +10.19%
Feb 7, 2020
Downgrades: Market Perform
Price Target: $306 → $275
Current: $168.59
Upside: +63.12%